Clinical trials: Thrombi
Ischemic Heart Disease, Angina Pectoris
XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE Xpedition SV Japan PMS)
The objective of the study is to evaluate the safety and efficacy of XIENCE Xpedition Everolimus-Eluting 2.25mm Stent in real world practice in Japanese hospitals.
- Conditions
- Ischemic Heart Disease, Angina Pectoris, Coronary Artery Disease, Myocardial Ischemia
- Trial name
- NCT02513732
- Testing
- XIENCE Xpedition 2.25 mm stent
- Where
- 11 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Abbott Medical Devices
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
The primary objective was to demonstrate the dose-response of Semuloparin sodium (AVE5026) for the prevention of Venous Thromboembolism [VTE] in patients undergoing total knee replacement [TKR] surgery.
- Trial name
- TREK (NCT00331838)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 19 sites in Argentina, Bulgaria and 17 more
- Volunteers
- 705 people
- Sponsor
- Sanofi
Retinal Vein Occlusion, Macular Oedema
Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion
The purpose of this study is to use retrospective data to evaluate the efficacy, safety and re-injection interval of OZURDEX® in the treatment of macular oedema due to retinal vein occlusion (RVO) in patients who received…
- Trial name
- NCT01566526
- Testing
- dexamethasone intravitreal implant 0.7 mg
- Where
- Belgium
- Volunteers
- 26 people
- Sponsor
- Allergan
End Stage Renal Disease, Thrombosis
Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis
This study evaluates the safety and efficacy of AB002 (E-WE thrombin) in patients with end stage renal disease on chronic hemodialysis. Two dose levels will be evaluated in two cohorts.
- Trial name
- NCT03963895
- Testing
- AB002 Dose 1, AB002 Dose 2
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Aronora, Inc.
Arterial Occlusive Diseases
Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion
The purpose of the trial is to evaluate the safety and efficacy of microplasmin administration in patients with acute peripheral arterial occlusion.
- Trial name
- NCT00123292
- Testing
- Microplasmin
- Where
- Belgium
- Volunteers
- 19 people
- Sponsor
- ThromboGenics
Peripheral Venous Thrombosis, Peripheral Arterial Thrombosis
JETi Hong Kong Post Market Study (PMS)
The JETi Hong Kong PMS is a single-arm, multicenter study to collect real-world data on the safety, performance, and clinical benefits of the JETi System for the treatment of acute and subacute thrombosis in the peripheral…
- Conditions
- Peripheral Venous Thrombosis, Peripheral Arterial Thrombosis, Peripheral Arteriovenous Thrombosis
- Trial name
- NCT06340763
- Testing
- JETi Hydrodynamic Thrombectomy System
- Where
- 4 sites in Hong Kong
- Volunteers
- 12 people
- Sponsor
- Abbott Medical Devices
Abdominal Neoplasms
Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery
The primary objective of this study is to evaluate the effects of enoxaparin on venous thromboembolism incidence and bleeding rate (major and minor bleeding) in patients undergoing curative abdominal cancer surgery.
- Trial name
- NCT00723216
- Testing
- enoxaparin, Physical prophylaxis
- Where
- Japan
- Volunteers
- 151 people
- Sponsor
- Sanofi
Atrial Fibrillation
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region
This international study is a prospective noninterventional observational cohort study of patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or…
- Trial name
- XANTUS-EL (NCT01800006)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 17 sites in Argentina, Azerbaijan and 15 more
- Volunteers
- 2,101 people
- Sponsor
- Bayer
Deep Vein Thrombosis Leg, DVT
ClotTriever Outcomes (CLOUT) Registry
Evaluate real world patient outcomes after treatment of acute, subacute, and chronic proximal lower extremity deep vein thrombosis (DVT) with the ClotTriever Thrombectomy System.
- Conditions
- Deep Vein Thrombosis Leg, DVT, Chronic DVT of Lower Extremity, Acute DVT of Lower Extremity
- Trial name
- CLOUT (NCT03575364)
- Testing
- ClotTriever
- Where
- 43 sites in United States
- Volunteers
- 499 people
- Sponsor
- Inari Medical
Deep Vein Thrombosis, DVT
BOLT-DVT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
The objective of this study is to demonstrate the safety and efficacy of the Indigo Aspiration system for percutaneous mechanical thrombectomy in a population presenting with obstruction due to deep vein thrombosis (DVT) who are…
- Trial name
- NCT05003843
- Testing
- Indigo Aspiration System
- Where
- 42 sites in United States
- Volunteers
- 229 people
- Sponsor
- Penumbra Inc.
Pulmonary Embolism
Endovascular Engineering ENGULF Study
Evaluation of initial safety and clinical feasibility of the Hēlo PE Thrombectomy System for thrombectomy in acute submassive pulmonary embolism (PE).
- Trial name
- ENGULF (NCT05597891)
- Testing
- Hēlo PE Thombectomy System
- Where
- 21 sites in United States
- Volunteers
- 177 people
- Sponsor
- Endovascular Engineering
Acute Ischemic Stroke
Safety and Efficacy Evaluation of the Ceretrieve Device in the Treatment of AIS Patients
The main objective of this clinical trial is to evaluate of the safety \& efficacy of the Ceretrieve device within 24 hours post thrombectomy procedure.
- Trial name
- NCT06733246
- Testing
- Aspiration 0
- Where
- Germany
- Volunteers
- 132 people
- Sponsor
- Ceretrieve Ltd.
Venous Thromboembolism
A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA
This is a Phase 2, multicenter, randomized, open-label, parallel group, blinded endpoint evaluation, active-controlled, dose-finding study.This study is designed to compare the efficacy and safety of 3 dose levels of SRSD107 and…
- Trial name
- NCT07140523
- Testing
- SRSD107, enoxaparin
- Where
- Czechia
- Volunteers
- 450 people
- Sponsor
- Sirius Therapeutics Co., Ltd.
Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO
This is an observational study in which data already collected from people with the eye disorders below are studied. In observational studies, only observations are made without participants receiving any advice or any changes to…
- Trial name
- AIRSPEED (NCT06495203)
- Testing
- anti-VEGF treatment
- Where
- Canada
- Volunteers
- 1,350 people
- Sponsor
- Bayer
Venous Thromboembolism (VTE)
Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners
Patients with cancer are at a significantly increased risk of experiencing a venous thromboembolism (VTE). VTE is defined by a blood clot in the leg or lower extremity (deep vein thrombosis) or a blood clot in the lung (pulmonary…
- Trial name
- PRACTISE (NCT03965741)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban(Eliquis), Pradaxa (Dabigatran etexilate)
- Where
- Sweden
- Volunteers
- 97,765 people
- Sponsor
- Bayer
Thrombophlebitis Leg
Phlogenzym® in Patients With Acute Thrombophlebitis - Efficacy and Tolerance
Oral enzyme therapy in patients with acute superficial vein inflammation (thrombophlebitis) can serve as an additional treatment option besides standard therapy with compression stockings, common pain medication and physical…
- Trial name
- NCT03470337
- Testing
- Phlogenzym
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Mucos Pharma GmbH & Co. KG
Visual Impairment, Macular Edema
Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)
This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant® after 6 months of treatment. In the study arm Lucentis will be given monthly in a pro re nata scheme whereas the comparator…
- Conditions
- Visual Impairment, Macular Edema, Central Retinal Vein Occlusion
- Trial name
- COMRADE-C (NCT01396083)
- Testing
- Ranibizumab
- Where
- 64 sites in Germany, Hungary and 2 more
- Volunteers
- 243 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema, Branch Retinal Vein Occlusion
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at…
- Trial name
- BALATON (NCT04740905)
- Testing
- Faricimab, Aflibercept
- Where
- 150 sites in United States, Argentina and 20 more
- Volunteers
- 553 people
- Sponsor
- Hoffmann-La Roche
Venous Thrombosis
Phase I Study of Direct Coagulation Factor Xa Inhibitor SYHA136 Tablets in Chinese Healthy Volunteers
The trial used single-center, randomized, double-blind, placebo-controlled, single-dose ascending study. The trial planned to enroll fifty-six healthy volunteers.
- Trial name
- NCT04036656
- Testing
- SYHA136 0.5 mg, SYHA136 1 mg, SYHA136 2.5 mg
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Coronary Disease, Coronary Artery Disease
SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe
The purpose of this Clinical Evaluation is a continuation in the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of patients with de novo coronary artery…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- SPIRIT V (NCT00402272)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent
- Where
- 93 sites in Austria, Belgium and 21 more
- Volunteers
- 2,700 people
- Sponsor
- Abbott Medical Devices